No products in the cart.
Pre-made Tebentafusp benchmark antibody ( scFv Fusion, anti-CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-555
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tebentafusp biosimilar, scFv Fusion, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
The drug, tebentafusp, is a type of treatment called a bispecific fusion protein. It works by helping immune cells get close enough to cancer cells to attack them. The clinical trial evaluated the drug as an initial treatment for people with metastatic uveal melanoma.
| Products Name (INN Index) | Pre-Made Tebentafusp biosimilar, scFv Fusion, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
|---|---|
| INN Name | Tebentafusp |
| Target | CD3E |
| Format | scFv Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Immunocore,MedImmune |
| Conditions Approved | NA |
| Conditions Active | Malignant melanoma,Uveal melanoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD3E |
| Package |
Previous slide
Next slide
